AML-loaded DC generate Th1-type cellular immune responses in vitro

Cytotherapy

Volumn 8, Issue 2, 2006, Pages 95-104

  Xing, Dongxia ^a   Decker, W K ^a   Li, S ^a   Robinson, S N ^a   Yang, H ^a   Segal, H ^b   O'Connor, S ^a   Yao, X ^a   Komanduri, K V ^a   McMannis, J D ^a   Jones, R B ^a   de Lima, M ^a   Champlin, R E ^a   Shpall, E J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Ag processing presentation; AML; Cytotoxic T lymphocyte; DC

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BLAST CELL; CELL ISOLATION; CELL KILLING; CELL LYSATE; CELL MATURATION; CELL MIGRATION; CELL SELECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DONOR; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL;

ACUTE DISEASE; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD14; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-6; LEUKEMIA; LEUKEMIA, MYELOID; LINEAR MODELS; LYMPHOCYTE ACTIVATION; MONOCYTES; PHAGOCYTOSIS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646419552     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240600620093     Document Type: Article

References (35)

1. Hirano, N and Takahashi, T and Ohtake, S and et al. (1996) Expression of costimulatory molecules in human leukemias Leukemia, 10, pp. 1168-76.
2. Notter, M and Willinger, T and Erben, U and Thiel, E. (2001) Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells Blood, 94, pp. 3138-45.
3. Buzyn, A and Petit, F and Ostankovitch, M and et al. (1999) Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients Blood, 9, pp. 3135-40.
4. Buggins, AG and Lea, N and Gaken, J and et al. (1999) Effect of costimulation and the microenvironment on antigen presentation by leukemic cells Blood, 94, pp. 3479-90.
5. Fong, L and Engleman, EG. (2000) Dendritic cells in cancer immunotherapy Annu Rev Immunol, 18, pp. 245-73.
6. Banchereau, J and Steinman, RM. (1998) Dendritic cells and the control of immunity Nature, 392, pp. 245-52.
7. Mayordomo, JI and Zorina, T and Storkus, WJ and et al. (1997) Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines Stem Cells, 15, pp. 94-103.
8. Song, W and Song, WL and Carpenter, H and et al. (1997) Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity J Exp Med, 186, pp. 1247-56.
9. Specht, JM and Wang, G and Do, MT and et al. (1997) Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases J Exp Med, 186, pp. 1213-21.
10. Boczkowski, D and Nair, SK and Nam, JH and et al. (2000) Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells Cancer Res, 60, pp. 1028-34.
11. Geiger, JD and Hutchinson, RJ and Hohenkirk, LF and et al. (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression Cancer Res, 61, pp. 8513-9.
12. Nestle, FO and Alijagic, S and Gilliet, M and et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med, 4, pp. 328-32.
13. Molldrem, JJ and Clave, E and Jiang, YZ and et al. (1997) Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units Blood, 90, pp. 2529-34.
14. Nouri-Shirazi, M and Banchereau, J and Bell, D and et al. (2000) Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses J Immunol, 165, pp. 3797-803.
15. Ohminami, H and Yasukawa, M and Fujita, S. (2000) HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide Blood, 95, pp. 286-93.
16. Oka, Y and Elisseeva, OA and Tsuboi, A and et al. (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product Immunogenetics, 51, pp. 99-107.
17. Sman, Y and Takahashi, M and Zheng, Z and et al. (1999) Dendritic cells stimulate the expansion of antileukemia immunotherapy J Exp Clin Cancer Res, 18, pp. 485-92.
18. Sivastava, BI and Srivastava, A and Srivastava, MD. (1994) Phenotype, genotype and cytokine production in acute leukemia involving progenitors of dendritic Langerhans' cells Leukemia Res, 18, pp. 499-511.
19. Choudhury, A and Gajewski, JL and Liang, JC and et al. (1997) Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia Blood, 89, pp. 1133-42.
20. Choudhury, BA and Liang, JC and Thomas, EK and et al. (1999) Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses Blood, 93, pp. 780-86.
21. Charbonnier, A and Gaugler, B and Sainty, D and et al. (1999) Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias Eur J Immunol, 29, pp. 2567-78.
22. Cignetti, A and Bryant, E and Allione, B and et al. (1999) CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells Blood, 94, pp. 2048-55.
23. Houtenbos, I and Westers, TM and Stam, AG and et al. (2003) Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation Cancer Immunol Immunother, 52, pp. 455-62.
24. Ossenkoppele, GJ and Stam, AG and Westers, TM and et al. (2003) Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells Leukemia, 17, pp. 1424-6.
25. Klammer, M and Waterfall, M and Samuel, K and et al. (2005) Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia Br J Haematol, 129, pp. 340-9.
26. Gong, S and Koido, Y and Kato, Y and et al. (2004) Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts Leukemia Res, 28, pp. 805-16.
27. Forster, R and Schubel, A and Breitfeld, D and et al. (1999) CCR7 Coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs Cell, 99, pp. 23-33.
28. Scandella, E and Men, Y and Gillessen, S and et al. 2002 Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood, 100, pp. 1354-61.
29. Scandella, E and Men, Y and Legler, DF and et al. (2004) CCL19/ CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2 Blood, 103, pp. 1595-601.
30. Phan, GQ and Wang, E and Marincola, FM. (2001) T-cell directed cancer vaccines: Mechanisms of immune escape and immune tolerance Expert Opin Biol Ther, 1, pp. 511-23.
31. Spisek, R and Chevallier, P and Morineau, N and et al. (2002) Induction of leukemia-specific cytotoxic response by cross-presentation of late apoptotic leukemic blast by autologous dendritic cells of nonleukemic origin Cancer Res, 15, pp. 2861-68.
32. Nouri-Shirazi, M and Banchereau, J and Fay, J and Palucka, K. (2000) Dendritic cells based tumor vaccines Immunol Lett, 15, pp. 5-10.
33. Molldrem, J and Dermime, S and Parker, K and et al. (1996) Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood, 88, pp. 2450-7.
34. Ludewig, B and Odermatt, B and Ochsenbein, AF and et al. (1999) Role of dendritic cells in the induction and maintenance of autoimmune diseases Immunol Rev, 169, pp. 45-54.
35. Lee, JJ and Kook, H and Park, MS and et al. (2004) Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation J Clin Apheresis, 19, pp. 66-70.